Elicio Therapeutics (ELTX) Company Overview

Profile

Full Name:

Elicio Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

February 5, 2021

Indexes:

Not included

Description:

Elicio Therapeutics (ELTX) is a biotechnology company focused on developing innovative cancer treatments. They use a unique platform to create therapies that stimulate the immune system, helping the body fight cancer more effectively. Their goal is to improve patient outcomes and advance cancer care.

Events Calendar

Earnings

Next earnings date:

Mar 28, 2025

Recent quarterly earnings:

Nov 13, 2024

Recent annual earnings:

Mar 29, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Jun 2, 2023

Analyst ratings

Recent major analysts updates

Oct 31, 24 Jones Trading
Buy
Aug 23, 24 HC Wainwright & Co.
Buy
Jun 6, 24 HC Wainwright & Co.
Buy
May 22, 24 HC Wainwright & Co.
Buy
May 1, 24 HC Wainwright & Co.
Buy
Apr 1, 24 Oppenheimer
Perform
Jan 17, 24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Why Elicio Therapeutics Inc (ELTX) Is Skyrocketing So Far In 2025
Why Elicio Therapeutics Inc (ELTX) Is Skyrocketing So Far In 2025
Why Elicio Therapeutics Inc (ELTX) Is Skyrocketing So Far In 2025
ELTX
Insider MonkeyFebruary 4, 2025

We have put together a list of the 15 healthcare stocks that are performing exceptionally well in 2025. In this article, we will examine how Elicio Therapeutics Inc (NASDAQ:ELTX) compares to other healthcare stocks. The healthcare industry is recovering in 2025 after two years of poor performance.

Elicio: Lymph Node Binding With ELI-002 Could Lead To Substantial 1st Half 2025 Data
Elicio: Lymph Node Binding With ELI-002 Could Lead To Substantial 1st Half 2025 Data
Elicio: Lymph Node Binding With ELI-002 Could Lead To Substantial 1st Half 2025 Data
ELTX
seekingalpha.comJanuary 31, 2025

Interim analysis from the phase 1/2 AMPLIFY-7P study, using ELI-002 for the treatment of KRAS mutant pancreatic cancer patients, is expected in the 1st half of 2025. The global pancreatic cancer market size is expected to reach $7.4 billion by 2032; It is said that approximately 88% of PDAC cases deal with the KRAS mutation. The company has already established a proposed phase 3 design with the FDA in a Type B meeting using ELI-002 for the treatment of patients with KRAS-mutant pancreatic cancer.

Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy
Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy
Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy
ELTX
globenewswire.comJanuary 22, 2025

Received supportive FDA feedback on key elements of the potential ELI-002 Phase 3 study design, including dose, schedule, patient population and primary endpoint analysis

Elicio Therapeutics Reports Inducement Grants
Elicio Therapeutics Reports Inducement Grants
Elicio Therapeutics Reports Inducement Grants
ELTX
globenewswire.comOctober 16, 2024

BOSTON, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on October 15, 2024, Elicio granted an aggregate of 5,900 inducement stock options to two new employees, as an inducement material to each individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Committee of Elicio's Board of Directors and granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan.

Elicio Therapeutics Reports Inducement Grants
Elicio Therapeutics Reports Inducement Grants
Elicio Therapeutics Reports Inducement Grants
ELTX
globenewswire.comSeptember 17, 2024

BOSTON, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on September 16, 2024, Elicio granted an aggregate of 4,800 inducement stock options to a new employee, as an inducement material to the individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Committee of Elicio's Board of Directors and granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan.

Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines
ELTX
globenewswire.comSeptember 13, 2024

BOSTON, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced upcoming presentations in September and October.

Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
ELTX
globenewswire.comAugust 13, 2024

• AMPLIFY-7P Phase 1 preliminary disease-free (“DFS”) survival demonstrates strong correlation between T cell response and reduced risk of progression or death•  AMPLIFY-7P Phase 1 data presented at ASCO demonstrated 100% of patients develop mKRAS-specific T-cell response with ~66% of responses including both CD4+ and CD8+ T cells•  Long term follow up of the AMPLIFY-201 Phase 1 study will be terminated, and long term follow up of the AMPLIFY-7P Phase 1 study will be minimized to collect only overall survival to preserve resources with updated data to be shared at upcoming medical meetings•  AMPLIFY-7P Phase 2 randomized clinical trial anticipated to complete 135-patient enrollment in the fourth quarter of 2024•  $43 million raised in 2024 funds Elicio into the second quarter of 2025

Why Is Elicio Therapeutics (ELTX) Stock Down 36% Today?
Why Is Elicio Therapeutics (ELTX) Stock Down 36% Today?
Why Is Elicio Therapeutics (ELTX) Stock Down 36% Today?
ELTX
investorplace.comJune 28, 2024

Elicio Therapeutics (NASDAQ: ELTX ) stock is falling on Friday after the clinical-stage biotechnology company announced a proposed public offering. Elicio Therapeutics has announced its plans for a public offering that will include shares of ELTX stock, warrants to purchase additional shares and pre-funded warrants.

Elicio Therapeutics Announces Proposed Public Offering
Elicio Therapeutics Announces Proposed Public Offering
Elicio Therapeutics Announces Proposed Public Offering
ELTX
globenewswire.comJune 27, 2024

BOSTON, June 27, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it has commenced an underwritten public offering of its shares of common stock and accompanying common warrants and, in lieu of its shares of common stock to certain investors that so choose, pre-funded warrants to purchase shares of common stock and accompanying common warrants. All of the common stock, pre-funded warrants and accompanying common warrants are being offered by Elicio. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P
Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P
Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P
ELTX
globenewswire.comJune 27, 2024

ELI-002 7P administered as a monotherapy at the Phase 2 dose shows preliminary encouraging Disease-Free Survival data in pancreatic ductal adenocarcinoma ELI-002 7P administered as a monotherapy at the Phase 2 dose shows preliminary encouraging Disease-Free Survival data in pancreatic ductal adenocarcinoma

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the ticker symbol for Elicio Therapeutics?
  • Does Elicio Therapeutics pay dividends?
  • What sector is Elicio Therapeutics in?
  • What industry is Elicio Therapeutics in?
  • What country is Elicio Therapeutics based in?
  • When did Elicio Therapeutics go public?
  • Is Elicio Therapeutics in the S&P 500?
  • Is Elicio Therapeutics in the NASDAQ 100?
  • Is Elicio Therapeutics in the Dow Jones?
  • When was Elicio Therapeutics's last earnings report?
  • When does Elicio Therapeutics report earnings?
  • Should I buy Elicio Therapeutics stock now?

What is the ticker symbol for Elicio Therapeutics?

The ticker symbol for Elicio Therapeutics is NASDAQ:ELTX

Does Elicio Therapeutics pay dividends?

No, Elicio Therapeutics does not pay dividends

What sector is Elicio Therapeutics in?

Elicio Therapeutics is in the Healthcare sector

What industry is Elicio Therapeutics in?

Elicio Therapeutics is in the Biotechnology industry

What country is Elicio Therapeutics based in?

Elicio Therapeutics is headquartered in United States

When did Elicio Therapeutics go public?

Elicio Therapeutics's initial public offering (IPO) was on February 5, 2021

Is Elicio Therapeutics in the S&P 500?

No, Elicio Therapeutics is not included in the S&P 500 index

Is Elicio Therapeutics in the NASDAQ 100?

No, Elicio Therapeutics is not included in the NASDAQ 100 index

Is Elicio Therapeutics in the Dow Jones?

No, Elicio Therapeutics is not included in the Dow Jones index

When was Elicio Therapeutics's last earnings report?

Elicio Therapeutics's most recent earnings report was on Nov 13, 2024

When does Elicio Therapeutics report earnings?

The next expected earnings date for Elicio Therapeutics is Mar 28, 2025

Should I buy Elicio Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions